211
Views
33
CrossRef citations to date
0
Altmetric
Commentary

Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses

, &
Pages 1303-1308 | Accepted 05 Mar 2008, Published online: 15 Apr 2008

References

  • Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997; 350:503–8
  • MacLean CH, Knight K, Paulus H, et al. Costs attributable to osteoarthritis. J Rheumatol 1998;25:2213–8
  • Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41: 778–99
  • Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385–91
  • du Souich P, Vergès J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther 2001; 70:5–9
  • Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–55
  • Zhang W, Moskowitz RW. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence activity. Osteoarthritis Cartilage 2007;15:981–9
  • Fajardo M, Di Cesare PE. Disease-modifying therapies for osteoarthritis: current status. Drugs Aging 2005;22:141–61
  • Hardingham T. Chondroitin sulfate and joint disease. Osteoarthritis Cartilage 1998;6(Suppl A):3–5
  • Volpi N. The pathobiology of osteoarthritis and the rationale for using chondroitin sulfate for its treatment. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:119–27
  • Bali JP, Cousse H, Neuzil E. Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Semin Arthritis Rheum 2001;31:58–68
  • Monfort J, Pelletier J-P, Garcia-Giralt N, Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulfate on osteoarthritis articular tissues. Ann Rheum Dis 2007;doi:10.1136/ard.2006.068882
  • Simanek V, Kren V, Ulrichova J, Gallo J. The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: are these saccharides drugs or nutraceuticals? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005;149:51–6
  • Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6(Suppl A):39–46
  • Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004;12:269–76
  • Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779–86
  • Kahan A, Reginster J-Y, Vignon E. STOPP (STudy on Osteoarthritis Progression Prevention): a new two-year trial with chondroitin 4 & 6 sulfate (CS). Accessed at URL: http://www.ibsach.com/eular_2006_amsterdam_vignon-2.pdf, date September 20, 2006
  • Gross JI, Mathews MB, Dorfman A. Sodium chondroitin sulfate-protein complexes of cartilage. II. Metabolism. J Biol Chem 1960;235:2889–92
  • Hutterer F. Degradation of mucopolysaccharides by hepatic lysosomes. Biochim Biophys Acta 1966;115:312–9
  • Andermann G, Dietz M. The influence of the route of administration on the bioavailability of an endogenous macromolecule: chondroitin sulphate (CSA). Eur J Drug Metab Pharmacokinet 1982;7:11–6
  • Konador A, Kawiak J. Changes in chondroitin sulfate concentration in rabbit blood plasma depending on the method of its administration. Arch Immunol Ther Exp (Warsz) 1977;25:895–903
  • Wood KM, Wusteman FS, Curtis CG. The metabolic fate of chondroitin (35S) sulphate proteoglycan in the rat. Biochem Soc Trans 1975;3: 500–2
  • Konador A, Kawiak J. Distribution of radioactivity in the mouse organism after administration of 35S-chondroitin sulphate. Folia Biol (Krakow) 1976;24:177–90
  • Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205–11
  • McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. J Am Med Assoc 2000;283:1469–75
  • Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514–22
  • Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007;146:580–90
  • Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007;11:125–38
  • Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New Engl J Med 2006;354:795–808
  • Helg AG, de Vathaire F. How solid are the results of the metaanalysis by Reichenbach et al. and its conclusions? [Letter]. http://www.annals.org/cgi/eletters/146/8/580#15862, accessed at URL, date 30 November 2007
  • Pelletier JP. Chondroitin sulfatemeta-analysis: the jury is not yet out. [Letter]. http://www.annals.org/cgi/eletters/146/8/580#15862, accessed at URL, date 16 May 2007
  • Goldberg HA, Avins AL. Interpretation of chondroitin meta-analysis. [Letter].: http://www.annals.org/cgi/eletters/146/8/580#15862, accessed at URL, date 23 April 2007
  • du Souich P. Clinical usefulness of chondroitin sulphate. [Letter]. http://www.annals.org/cgi/eletters/146/8/580#15862, accessed at URL, date 19 April 2007
  • Bourgeois P, Chales G, Dehais J, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6(Suppl A):25–30
  • Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6(Suppl A):39–46
  • Pavelka K, Manopulo R, Busci L. Double-blind, dose-effect study of oral chondroitin 4 & 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rheumatologica 1999;24: 21–30
  • Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New Engl J Med 2006;354:795–808
  • Omata T, Itokazu Y, Inoue N, Segawa Y. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen- induced arthritis. Arzneimittelforschung 2000;50:148–53
  • Mazières N, Hucher M, Zaïm M, Garnero P. Effect of chondroitin sulfate in symptomatic knee osteoarthritis: a multicenter, randomized, double blind, placebo-controlled study. Ann Rheum Dis 2007;66:639–45
  • Pham T, van der Heijde D, Altman RD, et al. OMERACT- OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389–99
  • Hathcock JN, Shao A. Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol 2007;47: 78–83
  • Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007;24:57–80

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.